Pulse Pressure Predicts Incident Cardiovascular Disease but Not Diabetic Nephropathy in Patients With Type 1 Diabetes (The FinnDiane Study)

April 2011
Diabetes Care;Apr2011, Vol. 34 Issue 4, p886
Academic Journal
OBJECTIVE--Pulse pressure (PP), an estimate of arterial stiffness, has been shown to be associated with incident cardiovascular disease (CVD) in patients with type 1 diabetes (T1D). However, diabetic kidney disease, a strong predictor of CVD, was not previously taken into account. Furthermore, the role of PP as a predictor of diabetic nephropathy is not known. Therefore, we prospectively investigated the associations between PP and these diabetes complications in patients with T1D. RESEARCH DESIGN AND METHODS--A total of 4,509 patients from the FinnDiane Study participated. Follow-up data on incident CVD events and renal status (median 5.3 years) were available in 69 and 76% of the patients, respectively. Altogether, 269 patients (8.6%) had an incident CVD event and 370 patients (10.8%) progressed to a higher level of albuminuria or to end-stage renal disease. RESULTS--PP was higher at baseline in patients who experienced a CVD event (66 ± 18 vs. 52 ± 14 mmHg; P < 0.001) or progressed in their renal status (58 ± 18 vs. 54 ± 15 mmHg; P < 0.01) during follow-up. In a Cox regression model, PP was independently associated with a first ever CVD event (hazard ratio per 10 mmHg 1.22 [95% CI 1.10-1.34]) but not progression of renal disease (1.00 [0.89-1.12]) after adjustments for traditional risk factors. CONCLUSIONS--PP, a marker of arterial stiffness, is a risk factor for cardiovascular complications but not for diabetic nephropathy in patients with T1D.


Related Articles

  • A1C Variability Predicts Incident Cardiovascular Events, Microalbuminuria, and Overt Diabetic Nephropathy in Patients With Type 1 Diabetes. Wadén, Johan; Forsblom, Carol; Thorn, Lena M.; Gordin, Daniel; Saraheimo, Markku; Groop, Per-Henrik // Diabetes;Nov2009, Vol. 58 Issue 11, p2649 

    OBJECTIVE--Recent data from the Diabetes Control and Complications Trial (DCCT) indicated that A1C variability is associated with the risk of diabetes microvascular complications. However, these results might have been influenced by the interventional study design. Therefore, we investigated the...

  • Progression of microalbuminuria in type 1 diabetes: Ten-year prospective observational study. Rossing, Peter; Hougaard, Philip; Parving, Hans-Henrik // Kidney International;Oct2005, Vol. 68 Issue 4, p1446 

    Examines the presence of persistent microalbuminaria as established predictor of development of overt diabetic nephropathy. Increase in risk of cardiovascular disease; Determination of the progressive renal insufficiency; Rate of progression of urinary albumin excretion rate.

  • Neutrophil Gelatinase-Associated Lipocalin as an Early Biomarker of Nephropathy in Diabetic Patients. Bolignano, Davide; Lacquaniti, Antonio; Coppolino, Giuseppe; Donato, Valentina; Fazio, Maria Rosaria; Nicocia, Giacomo; Buemi, Michele // Kidney & Blood Pressure Research;2009, Vol. 32 Issue 2, p91 

    Background/Aims: Renal tubulointerstitium plays an important role in the development and progression of diabetic nephropathy. Methods: With the present study, we aimed at evaluating the levels of neutrophil gelatinase-associated lipocalin (NGAL), a tubular stress protein, in serum (sNGAL) and...

  • Progressive Renal Decline: The New Paradigm of Diabetic Nephropathy in Type 1 Diabetes. Krolewski, Andrzej S. // Diabetes Care;Jun2015, Vol. 38 Issue 6, p954 

    On the basis of extensive studies in Joslin Clinic patients over 25 years, we propose a new model of diabetic nephropathy in type 1 diabetes. In this model, the predominant clinical feature of both early and late stages of diabetic nephropathy is progressive renal decline, not albuminuria....

  • Quantitative evaluation of proteinuria for health checkups is more efficient than the dipstick method. Nagai, Kei; Yamagata, Kunihiro // Clinical & Experimental Nephrology;Feb2015, Vol. 19 Issue 1, p152 

    No abstract available.

  • Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy. Jacobsen, Peter; Parying, Hans-Henrik // Kidney International Supplement;Nov2004, Issue 92, pS108 

    Beneficial impact on cardiovascular risk factors by dual blockade of the rennin-angiotensin system in diabetic nephropathy.Background.Patients with diabetic nephropathy have a high risk of cardiovascular disease and end-stage renal disease. Dual blockade of the renin-angiotensin system (RAS)...

  • Renal complications of diabetes. Min, T.Z.; Stephens, M.W.; Kumar, P.; Chudleigh, R.A. // British Medical Bulletin;Dec2012, Vol. 104 Issue 1, p113 

    Introduction Diabetic nephropathy is a leading cause of chronic kidney disease (CKD) in the UK. These patients are at significantly increased risk of cardiovascular disease and of progression to end-stage renal disease. We review the epidemiology, pathogenesis and natural history of diabetic...

  • Renal Disease in Cardiovascular Disorders: An Underrecognized Problem. Baumelou, Alain; Bruckert, Eric; Bagnis, Corinne; Deray, Gilbert // American Journal of Nephrology;Mar/Apr2005, Vol. 25 Issue 2, p95 

    Chronic renal disease is generally appreciated as a major and rapidly growing health problem. In the United States alone, as many as 19.5 million people may have markers of early renal disease, and more than 660,000 people are expected to require renal replacement therapy by the year 2010. By...

  • Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Rossing, Kasper; Mischak, Harald; Parving, Hans-Henrik; Christensen, Per K.; Walden, Michael; Hillmann, Meike; Kaiser, Thorsten // Kidney International;Jul2005, Vol. 68 Issue 1, p193 

    Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Background. New insights into the pathogenesis and treatment of diabetic renal disease may emerge from recent advances in proteomics using high-throughput mass spectrometry (MS) of urine....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics